Breast Cancer Vaccine Candidate Shows Positive Early Trial Results
Anixa Biosciences announced positive Phase 1 trial findings for its Alpha-Lactalbumin breast cancer vaccine. The study met its primary endpoints, with 74% of participants showing protocol-defined immune responses. This represents an encouraging initial step in the development of a potential breast cancer vaccine.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.